Despite improvements in diagnosis and treatment, breast cancer still ranks as the number one cause of cancer-related death in women globally (
18). This study examined the potential of hWJMSCs-Se in reducing the effects of oxidative stress associated with breast cancer, specifically SK-BR3 cells.
It is well known that oxidative stress plays an important role in the onset and spread of cancer. Reactive oxygen species (ROS) can damage DNA, proteins, and lipids in cells, which can result in genetic abnormalities, aberrant cell signaling, and the promotion of tumors (
19). This work highlights the importance of oxidative stress in breast cancer biology and its therapeutic potential.
Mesenchymal stromal cells secrete a variety of bioactive compounds, including growth factors, cytokines, and extracellular vesicles, which have recently gained interest (
20). A number of factors, including ease of collection, low immunogenicity, and regenerative potential, make Wharton’s gel-derived MSCs promising (
21). The MSC-related immunomodulatory and tissue gene-generating properties are the focus of the study’s attention on hWJMSCs-Se, a cell approach (
22).
The findings demonstrated that hWJMSCs-Se therapy significantly lowers the viability and proliferation of SK-BR3 breast cancer cells. This finding implies that hWJMSCs-Se can prevent cancer cells from proliferating. The fact that this inhibition was time- and dose-dependent is significant since it suggests the possibility of individualized treatment approaches.
The induction of apoptosis in SK-BR3 cells after hWJMSCs-Se treatment is one of the main findings of the study. Apoptosis, a method of programmed cell death, is often blocked in cancer cells. Human Wharton’s jelly mesenchymal stem cell secretomes have the ability to induce selective death of cancer cells and spare healthy cells, as evidenced by its ability to accelerate apoptosis of breast cancer cells (
23).
The present study highlights the potential of hWJMSCs-Se in reducing proliferation and inducing apoptosis in SK-BR3 cells. Widowati et al. recently proposed that hWJMSCs effectively inhibited proliferation in T47D and MCF7 cell lines, with an IC50 value of 42.34% on MCF7 and 42.36% on T47D, and hWJMSCs significantly induced apoptotic genes P53, BAX, and caspase 9 expression in MCF7 and T47D cells, with no significant decrease in antiapoptotic gene BCL-2 (
24).
In contrast to the current study’s results, H. Sadeghi-aliabadi’s study reported limited effectiveness of WJMSC secretome therapies in inducing apoptosis and proliferation of A549 lung cancer cells.
Their response to doxorubicin showed no significant effects, suggesting the need for further investigation into the mechanisms underlying this phenomenon (
25).
Superoxide dismutase and catalase (CAT), two oxidation enzymes, can lower excessive ROS, a sign of oxidative stress (
26). This study showed that hWJMSCs-Se treatment significantly boosted the activity of these antioxidant enzymes in SK-BR3 cells. As to the current investigation, HWJMSC-SE might increase cell survival, reduce oxidative stress, and assist cancer cells in regaining their redox balance.
Disrupted redox balance is linked to angiogenesis, metastasis, and the growth of cancer in human cells. Mesenchymal stromal cells offer a superior alternative for treating ROS-induced damage linked to chronic diseases, such as cancer, dementia, and kidney failure, due to their therapeutic and regenerative capabilities (
27). Studies have suggested that MSCs might be used to treat specific disorders brought on by ROS (
27), which is consistent with the present study’s findings about the antioxidative properties of hWJMSCs-Se. Since MSCs can renew, regulate the immune system, and migrate, they represent a potential next-generation treatment with no adverse effects.
An essential step in the cancer mutase process is EMT (
28). The research shows that hWJMSCs-Se therapy results in alterations in EMT marker genes. Vimentin and N-cadherin expression are upregulated, although E-cadherin and -catenin levels are downregulated specifically. These are mesenchymal indicators. This finding shows that using hWJMSCs-Se to treat breast cancer cells might block the EMT process, potentially lowering the likelihood of breast cancer cells invading and spreading.
The process of ROS-induced EMT, which is essential for metastasis, might be connected to the development of chemoresistance (
29). It is worth noting that Ozge Cevik conducted WJMCS exosomes to suppress EMT signaling in cervical cancer cells as an effective paclitaxel drug delivery system (
30).
The findings of this study offer hope for the creation of novel therapies for HER2-positive breast cancer. Human Wharton’s jelly mesenchymal stem cell secretomes are interesting candidates for future targeted cancer therapies because they lower oxidative stress, prevent cell proliferation, induce apoptosis, and modify EMT pathways. Its non-invasive collecting method and immunomodulatory capabilities further boost its attractiveness as a therapeutic agent.
5.1. Conclusions
In conclusion, this study emphasizes hWJMSCs-Se’s ability to lessen the impacts of oxidative stress-induced breast cancer. The observed effects on cell survival, apoptotic induction, augmentation of antioxidant enzymes, and modification of EMT indicators demonstrate the broad therapeutic potential of hWJMSCs-Se. All the therapeutic implications of this novel strategy for treating breast cancer require further investigation and clinical trials.